935PD - Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer
| Autor: | Oaknin, A., Ellard, S.L., Leath III, C., Moreno, V., Kristeleit, R., Guo, W., Lu, S., Jenkins, D., McEachern, K., Yu Jen, K., Dunlap, S., Im, E., Gilbert, L. |
|---|---|
| Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|